This cluster groups 2 independently calculated changes: Cash & equivalents decreased 92.4%; Operating cash flow decreased 329.2%.
2 evidence-backed components· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTEstrella Immunopharma, Inc.'s latest supported as-filed period reports net income of -$2.3M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents decreased 92.4%; Operating cash flow decreased 329.2%.
2 evidence-backed componentsOperating cash flow changed -329.2% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
ESLA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001213900-26-098123SEC ↗4Aug 26, 2026Period Aug 25, 20260001996255-26-000004SEC ↗4Aug 25, 2026Period Aug 18, 20260001213900-26-093698SEC ↗8-KAug 21, 2026Period Aug 17, 20260001213900-26-092657SEC ↗10-QAug 13, 2026Period Jun 30, 20260001213900-26-089215SEC ↗8-KJun 30, 2026Period Jun 29, 20260001213900-26-073847SEC ↗10-QMay 18, 2026Period Mar 31, 20260001213900-26-058063SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 25, 2026Filed Aug 26, 2026 | Liu ChengCEO | Option ExerciseDirect | 100,000 | $0 | $0 | Form 4 ↗ |
| Aug 25, 2026Filed Aug 26, 2026 | Liu ChengCEO | Option ExerciseDirect | 100,000 | $1 | $81,500 | Form 4 ↗ |
| Aug 18, 2026Filed Aug 25, 2026 | Xu JiandongChief Financial Officer | Option ExerciseDirect | 100,000 | $1 | $81,500 | Form 4 ↗ |
| Aug 18, 2026Filed Aug 25, 2026 | Xu JiandongChief Financial Officer | Option ExerciseDirect | 100,000 | — | — | Form 4 ↗ |
| Oct 7, 2025Filed Apr 29, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating income changed +62.4% from the comparable as-filed period.
Research & development changed -70.0% from the comparable as-filed period.
Cash & equivalents changed -92.4% from the comparable as-filed period.
Working capital / assets changed -15246 basis points from the comparable as-filed period.
Shares outstanding changed +17.4% from the comparable as-filed period.
Total assets changed -38.8% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001213900-26-050433| Open Market PurchaseDirect |
| 1,000 |
| $1 |
| $1,330 |
| Form 4 ↗ |
| Sep 22, 2025Filed Apr 29, 2026 | Xu JiandongChief Financial Officer | Open Market PurchaseIndirect | 1,000 | $1 | $1,160 | Form 4 ↗ |
| Sep 11, 2025Filed Apr 29, 2026 | Xu JiandongChief Financial Officer | Open Market PurchaseDirect | 100 | $1 | $104 | Form 4 ↗ |
| Oct 30, 2024Filed Feb 14, 2025 | Xu JiandongChief Financial Officer | Grant Or AwardDirect | 490,796 | — | — | Form 4 ↗ |
| Oct 30, 2024Filed Feb 14, 2025 | Xu JiandongChief Financial Officer | Grant Or AwardDirect | 509,204 | — | — | Form 4 ↗ |
| Oct 30, 2024Filed Feb 14, 2025 | Liu ChengChief Executive Officer | Grant Or AwardDirect | 509,204 | — | — | Form 4 ↗ |
| Oct 30, 2024Filed Feb 14, 2025 | Liu ChengChief Executive Officer | Grant Or AwardDirect | 490,796 | — | — | Form 4 ↗ |
| Sep 29, 2023Filed Oct 5, 2023 | Owl Creek Asset Management, L.P.Reporting owner | OtherIndirect | 255,000 | $11 | $2.8M | Form 4 ↗ |